

Meet Luciana Borio, M.D., Assistant Commissioner for Counterterrorism Policy and Acting Deputy Chief Scientist



Dr. Luciana Borio serves as the Assistant Commissioner for Counterterrorism Policy and Director of the **[Office of Counterterrorism and Emerging Threats \(/AboutFDA/CentersOffices/OC/OfficeofScientificandMedicalPrograms/ucm197848.htm\)](#)** (OCET) in the **[Office of the Chief Scientist \(/AboutFDA/CentersOffices/OC/OfficeofScientificandMedicalPrograms/default.htm\)](#)**, U.S. Food and Drug Administration (FDA). In this capacity, Dr. Borio is responsible for providing leadership, coordination, and oversight for FDA's national and global health security, counterterrorism, and emerging threat portfolios. She serves as FDA's point of entry on policy and planning matters concerning counterterrorism and emerging

threats, and collaborates across the U.S. government and internationally on actions to advance global health security and U.S. national security.

Dr. Borio works in collaboration with other U.S. government agencies to define and prioritize requirements for medical countermeasures (MCMs) to respond to public health emergencies, coordinate research for evaluating MCMs, set strategies for deployment and use of MCMs, and facilitate access to MCMs during public health emergencies. Dr. Borio leads FDA's **[Medical Countermeasures Initiative \(/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/default.htm\)](#)** (MCMi), a key component of a broad U.S. government program to improve the United States' capacity to respond quickly and effectively to public health emergencies.

Dr. Borio was instrumental in coordinating FDA's response to the 2009 H1N1 influenza pandemic and continues to coordinate FDA's preparedness and response activities for emerging threats, such as the avian influenza A (H7N9) virus and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).

Dr. Borio also serves as the Acting Deputy Chief Scientist and is responsible for

providing leadership and coordination for FDA's cross-cutting scientific and public health efforts, including the **Advancing Regulatory Science Initiative (/ScienceResearch/SpecialTopics/RegulatoryScience/default.htm)**, and FDA's scientific professional development and scientific integrity efforts.

Prior to joining FDA in 2008, as a medical reviewer in the Center for Biologics Evaluation and Research, Dr. Borio was a Senior Associate at the UPMC Center for Biosecurity and an Assistant Professor of Medicine at the University of Pittsburgh from 2003 to 2008. Dr. Borio served at the U.S. Department of Health and Human Services as an Advisor on Biodefense Programs from 2001 to 2008, where she implemented and managed mathematical modeling projects to assess the health effects of bioterrorism on civilians and informed MCM procurement activities for the Office of Preparedness and Response.

Dr. Borio received her MD in 1996 from the George Washington University. She completed residency in 1999 in Internal Medicine at the New York Presbyterian Hospital - Cornell Medical Center and subsequently completed a combined fellowship in Infectious Diseases and Critical Care Medicine at Johns Hopkins University and the National Institutes of Health, respectively. Dr. Borio continues to practice medicine at Johns Hopkins Hospital.